Jonathan Rubin, SVP and Chief Medical Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership resulting from the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., effective November 2, 2026.
Timothy C. Dec, Senior Vice President and Chief Financial Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes to his beneficial ownership resulting from the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. that became effective on November …
SVRN, Inc. filed a Form 6-K on November 4, 2026, announcing the appointment of Patrick O'Kain as Chief Operating Officer effective November 3, 2026, following the resignation of David Schwed from that role.
Frank Mottola, SVP and Chief Technology Operations Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership of common stock and equity awards resulting from a merger that became effective on November 2, 2026.
Jack A. Khattar, Chief Executive Officer and Director of Supernus, Inc. (NASDAQ:SUPN), filed a Form 4 on November 4, 2026, disclosing changes in his beneficial ownership of common stock and equity awards resulting from the November 2, 2026 effective date of the merger between …
Director Georges Gemayel filed a Form 4 with the SEC on November 4, 2026, disclosing changes in beneficial ownership of Supernus, Inc. (NASDAQ:SUPN) common stock and equity awards resulting from the merger effective November 2, 2026, between Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Padmanabh P. Bhatt, SVP of IP and Chief Scientific Officer at Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership resulting from the November 2, 2026 merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc.
Director Bethany Sensenig filed a Form 4 with the SEC on November 4, 2026, disclosing the automatic conversion of her Supernus Pharmaceuticals equity awards into Supernus, Inc. equity awards following the completion of a merger on November 2, 2026.
Director Carrolee Barlow filed a Form 4 with the SEC on November 4, 2026, disclosing changes in beneficial ownership of Supernus, Inc. common stock and equity awards resulting from the merger effective November 2, 2026, in which Indivior Pharmaceuticals, Inc. merged with Supernus Pharmaceuticals, …
Carrolee Barlow, a newly appointed director of Supernus, Inc., filed a Form 3 initial statement of beneficial ownership on November 4, 2026, disclosing no beneficial ownership of company securities as of the event date of November 2, 2026.